心血管疾病中药材循证应用的最新进展-英文

上传人:豆浆 文档编号:48508419 上传时间:2018-07-16 格式:PPT 页数:28 大小:728.50KB
返回 下载 相关 举报
心血管疾病中药材循证应用的最新进展-英文_第1页
第1页 / 共28页
心血管疾病中药材循证应用的最新进展-英文_第2页
第2页 / 共28页
心血管疾病中药材循证应用的最新进展-英文_第3页
第3页 / 共28页
心血管疾病中药材循证应用的最新进展-英文_第4页
第4页 / 共28页
心血管疾病中药材循证应用的最新进展-英文_第5页
第5页 / 共28页
点击查看更多>>
资源描述

《心血管疾病中药材循证应用的最新进展-英文》由会员分享,可在线阅读,更多相关《心血管疾病中药材循证应用的最新进展-英文(28页珍藏版)》请在金锄头文库上搜索。

1、RMIT University10th SCICC, Guangzhou, China, 2008 Recent Progress in the Evidence-Based Application of Herbal Medicines for Cardiovascular Diseases Professor Shufeng Zhou, MD, PhD School of Health Sciences WHO Collaborating Center for Traditional Medicine RMIT University, Bundoora, Victoria 3083 Aus

2、tralia Phone: Tel: +61 3 9925 7794; Fax: +61 3 9925 7178 Email: shufeng.zhourmit.edu.au11 April 2008RMIT University10th SCICC, Guangzhou, China, 2008 An Overview of Global Herbal UseAll folk medicine includes the use of plant products.11,145 species of herbal plants worldwide; 534 species of plants

3、for Chinese Medicine.WHO definition botanical origin, without adulteration of any synthetic drugs.Legal status: food supplements (FDA drugs/health foods (SFDA of China).US$25 billion; market value 1015%/per year. 2 billion in Australia.40% Caucasian and 80% Asians use or used herbs.RMIT University10

4、th SCICC, Guangzhou, China, 2008 Active ComponentsBiotransformation ExcretionAbsorptionResponse/Toxicity?RMIT University10th SCICC, Guangzhou, China, 2008 Preclinical StagePhase IPhase IIPhase IIIPhase IVClinical Trials of Herbal MedicinesGeneral acceptance of humansSafety and EfficacyMore data on s

5、afety and EfficacyRMIT University10th SCICC, Guangzhou, China, 2008 Challenges for Herbal Clinical trials Dosage poor clinical studies Lack of ADR reporting systemRMIT University10th SCICC, Guangzhou, China, 2008 Types of Clinical Reports on Herb-Drug InteractionsN = 85RMIT University10th SCICC, Gua

6、ngzhou, China, 2008 What Herbs Interact with Drugs?N = 85RMIT University10th SCICC, Guangzhou, China, 2008 What Drugs Interact with Herbs?N = 85Drug Properties: narrow therapeutic index; extensive metabolism; substrates of CYPs and/or PgP.RMIT University10th SCICC, Guangzhou, China, 2008 HerbInterac

7、ting drugsDangguiWarfarinDanshen WarfarinGarlic Saquinavir, ritonavir, warfarin, chlorpropamide Ginkgo Trazodone, warfarin, digoxinGinsengAlcohol, phenelzine, warfarin HawthornDigoxin (no change)KavaAlcohol, alprazolam, bromazepam, L-dopaMilk thistleIndinavirPiperinePropranolol, rifampin, sparteine,

8、 theophylline, phenytoinRMIT University10th SCICC, Guangzhou, China, 2008 Toxicity due to Herb-Drug InteractionsHerb + DrugToxicitySJW + cyclosporine AOrgan rejectionSJW + oral contraceptivesBreakthrough bleeding SSRIs (sertraline Zoloft) Anticancer drug: irinotecan (CPT-11) Anticoagulants: warfarin

9、 (coumadin), phenprocoumon Antihistamine: fexofenadine Anti-HIV agents: PI: indinavir; RTI: nevirapine Bronchodilator: theophylline Hypoglycemics: tolbutamide Cardiovascualr drugs: digoxin, simvastatin Opiates: methadone, loperamide Oral contraceptives Sedatives: alprazolam & midazolam Immunosuppres

10、sants: cyclosporine & tacrolimusRMIT University10th SCICC, Guangzhou, China, 2008 RMIT University10th SCICC, Guangzhou, China, 2008 Mechanisms for Herb-Drug InteractionsDrug ResponseMetabolizing enzymes (CYPs) Identical TargetsTransporters (PgP)Different TargetsPharmacokinetics (PK)Pharmacodynamics

11、(PD)RMIT University10th SCICC, Guangzhou, China, 2008 Herb-CYP InteractionsHerbCYPs affectedSJWMost CYP (mainly CYP3A4)GarlicCYP2C, 2D, 2E, 3APiperineCYP1A, 2C, 3ALicorice CYP1A, 2A, 2C, 3AKavaCYP1A, 2C, 2D, 3A Ginseng CYP3A4, 2D, 2CGinkgo CYP2B, 3ABaizhiCYP1A, 2D, 2E, 3ADangguiCYP1A, 3ARMIT Univers

12、ity10th SCICC, Guangzhou, China, 2008 Herb-PgP InteractionsHerbModulation of PgPCurcumininhibitionHawthorn?GarlicInhibitionGinsengMostly inhibitionGreen teaInhibitionMilk thistleInhibitionPiperineInhibition SJWInductionRosemaryInhibitionRMIT University10th SCICC, Guangzhou, China, 2008 RMIT Universi

13、ty10th SCICC, Guangzhou, China, 2008 RMIT University10th SCICC, Guangzhou, China, 2008 Herbal Labeling What: identity, quantity of contents, identified active ingredient by common name or proprietary blend. How to use: route, dose daily, etc Who: name and place of manufacturer, packer or distributor

14、. What to claim “This statement has not been evaluated by the Food and Drug Administration”. “This product is not intended to diagnose, treat, cure, or prevent any diseases”.- “It is not advisable to use in combination with”RMIT University10th SCICC, Guangzhou, China, 2008 AcknowledgmentsProf. Guang

15、ji Wang Prof. Xiyong Yu Prof. Charlie Xue and Chunguang Li Prof. Eli Chan Prof. Wen Xie Prof. Tony Koon Prof. James W Paxton & Bruce Baguley Prof. John O Miners Prof. Ronald G Dickinson Prof. Min Huang & Anlong Xu Prof. Wei Duan Prof. Xiaotian Lee Prof. Ge Lin Prof. Qiang Zhang Prof. Yi-Zhun Zhu Nat

16、ional University of Singapore Academic Research Funds Singapore Cancer Syndicate RMIT University Grant for New Institute NICM grant of Australia Auckland Medical Research Foundation New Zealand Cancer Society Funds Maurice & Phyllis Paykel Trust Hu Zeping Tian Quan Zhang Jing Sun Zhuming Sun Feng Zhang Yaochung Linlin Wang Meredith Payne Liping Ya

展开阅读全文
相关资源
正为您匹配相似的精品文档
相关搜索

最新文档


当前位置:首页 > 商业/管理/HR > 其它文档

电脑版 |金锄头文库版权所有
经营许可证:蜀ICP备13022795号 | 川公网安备 51140202000112号